MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597964 | Name: Indinavir, threo-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Indinavir, threo- is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS.

Chemical Structure

Indinavir, threo-
Indinavir, threo-
CAS#360558-79-8

Theoretical Analysis

MedKoo Cat#: 597964

Name: Indinavir, threo-

CAS#: 360558-79-8

Chemical Formula: C36H47N5O4

Exact Mass: 613.3628

Molecular Weight: 613.80

Elemental Analysis: C, 70.45; H, 7.72; N, 11.41; O, 10.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Indinavir, threo-; Indinavir sulfate specified impurity C [EP]; Threo-indinavir;
IUPAC/Chemical Name
(S)-1-((2R,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
InChi Key
CBVCZFGXHXORBI-UVMOQAHJSA-N
InChi Code
InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29-,31+,32-,33+/m1/s1
SMILES Code
O=C([C@H]1N(C[C@H](O)C[C@@H](CC2=CC=CC=C2)C(N[C@@H]3[C@H](O)CC4=C3C=CC=C4)=O)CCN(CC5=CC=CN=C5)C1)NC(C)(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 613.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Aldeghi M, Malhotra S, Selwood DL, Chan AW. Two- and three-dimensional rings in drugs. Chem Biol Drug Des. 2014 Apr;83(4):450-61. doi: 10.1111/cbdd.12260. PubMed PMID: 24472495; PubMed Central PMCID: PMC4233953. 2: Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21. PubMed PMID: 23523594. 3: Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016 Dec;109:122-129. doi: 10.1016/j.ejpb.2016.09.014. Epub 2016 Sep 28. PubMed PMID: 27693678. 4: Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 2012 Feb;116(2):432-47. doi: 10.1097/ALN.0b013e3182423478. PubMed PMID: 22273859; PubMed Central PMCID: PMC3586934. 5: Huynh J, Hever A, Tom T, Sim JJ. Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. Int Urol Nephrol. 2011 Jun;43(2):571-3. doi: 10.1007/s11255-010-9751-6. Epub 2010 May 11. PubMed PMID: 20458537; PubMed Central PMCID: PMC3094655. 6: Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM. Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers. Intervirology. 2010;53(3):176-82. doi: 10.1159/000289341. Epub 2010 Mar 3. PubMed PMID: 20197684. 7: Ucisik MN, Dashti DS, Faver JC, Merz KM Jr. Pairwise additivity of energy components in protein-ligand binding: the HIV II protease-Indinavir case. J Chem Phys. 2011 Aug 28;135(8):085101. doi: 10.1063/1.3624750. PubMed PMID: 21895219; PubMed Central PMCID: PMC3182082. 8: Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM; BestQol Study Group. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Antivir Ther. 2004 Dec;9(6):979-85. PubMed PMID: 15651756. 9: Dicenzo R, Luque A, Larppanichpoonphol P, Reichman R. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother. 2006 Aug;58(2):393-400. Epub 2006 Jun 7. PubMed PMID: 16760191. 10: Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC Jr, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY; Protocol 054/069 Study Teams. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS. 2000 Sep 8;14(13):1973-8. PubMed PMID: 10997402. 11: Quintino MP, Nakamura MU, Simões Mde J, Araujo Júnior E, Filho RM, Torloni MR, Espiridião S, Kulay Júnior L. Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): biological assay. J Obstet Gynaecol Res. 2011 Sep;37(9):1212-5. doi: 10.1111/j.1447-0756.2010.01504.x. Epub 2011 Apr 26. PubMed PMID: 21518132. 12: The choice of HIV protease inhibitor: indinavir is currently the best option. Prescrire Int. 1999 Apr;8(40):55-60. Review. PubMed PMID: 10848067. 13: Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother. 2007 May;8(7):957-64. Review. PubMed PMID: 17472541. 14: Brandenburg JJ, Hoepelman IM, Stapper G, Lock MT. [Three patients with indinavir-related urolithiasis]. Ned Tijdschr Geneeskd. 2007 Aug 18;151(33):1839-45. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2007 Sep 15;151(37):2075-6. PubMed PMID: 17874643. 15: Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol. 2005 Mar;61(1):1-7. Epub 2005 Jan 22. PubMed PMID: 15666173. 16: Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998 Oct 29;339(18):1269-76. PubMed PMID: 9791142. 17: James JS. Crixivan (Indinavir): three doses daily, not two, in most regimens. AIDS Treat News. 1998 Oct 2;(No 304):4-5. PubMed PMID: 11365863. 18: Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:62-8. PubMed PMID: 14616416; PubMed Central PMCID: PMC1884318. 19: Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004 Mar;44(3):305-13. PubMed PMID: 14973305. 20: Trainor LD, Steinberg JP, Austin GW, Solomon HM. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Arch Pathol Lab Med. 1998 Mar;122(3):256-9. PubMed PMID: 9823864.